Phase II Trial of FANG Autologous Tumor Cell Vaccine in Advanced Melanoma
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary)
- Indications Malignant melanoma
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Gradalis
- 28 Jul 2017 Status changed from active, no longer recruiting to discontinued.
- 08 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 03 Jun 2014 Interim results of 6 studies combined, presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History